Zai Lab Limited - American Depositary Shares (NQ:ZLAB)

19.68 +0.16 (+0.85%)

Streaming Delayed Price Updated: 11:26 AM EST, Dec 3, 2025 Add to My Watchlist

Price and Volume

Volume	155,168
Open	19.42
Bid (Size)	19.67 (200)
Ask (Size)	19.73 (100)
Prev. Close	19.52
Today's Range	19.41 - 19.84
52wk Range	19.40 - 44.34
Shares Outstanding	956,637,360
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Nuvation Bio (NUVB) Soars on IBTROZI's Blockbuster Launch and Stellar Q3 2025 Performance

November 19, 2025

Boston, MA – November 19, 2025 – Nuvation Bio Inc. (NASDAQ: NUVB) has captured the financial spotlight, witnessing a remarkable 47.71% surge in its stock price following a stellar third-quarter 2025...

Via MarketMinute

Zai Lab Announces Third Quarter 2025 Financial Results and Recent Corporate Updates

November 06, 2025

From Zai Lab Limited

Via Business Wire

Performance

YTD	-20.7%	-20.7%
1 Month	-26.4%	-26.4%
3 Month	-41.0%	-41.0%
6 Month	-36.8%	-36.8%
1 Year	-32.6%	-32.6%

More News

Earnings Scheduled For November 6, 2025 ↗

November 06, 2025

Via Benzinga

Zai Lab Announces Participation in Investor Conferences in November and December 2025

October 31, 2025

From Zai Lab Limited

Via Business Wire

Zai Lab To Await More Trial Data Before Filing For Regulatory Approval For Experimental Cancer Drug ↗

September 03, 2025

Via Stocktwits

Earnings Scheduled For August 7, 2025 ↗

August 07, 2025

Via Benzinga

Zai Lab Announces Updated Phase 1 Data for Zocilurtatug Pelitecan (formerly ZL-1310), Demonstrating Potential as a First-in-Class/Best-in-Class DLL3-Targeted ADC for Small Cell Lung Cancer, and Initiation of Global Phase 3 Registrational Study

October 24, 2025

From Zai Lab Limited

Via Business Wire

Zai Lab to Announce Third Quarter 2025 Financial Results and Recent Corporate Updates on November 6, 2025

October 15, 2025

From Zai Lab Limited

Via Business Wire

Zai Lab Announces Oral Presentation of Updated Data from Global Phase 1 Trial of Zocilurtatug Pelitecan (ZL-1310), a Potential First-in-Class DLL3-Targeted ADC, at 2025 AACR-NCI-EORTC Conference

October 13, 2025

From Zai Lab Limited

Via Business Wire

Zai Lab's Double Whammy: Earnings Miss, Phase 3 Setback ↗

September 11, 2025

Via Benzinga

China-Tied Biotechs Zai Labs, BeOne Plunge On Rumored Executive Order ↗

September 10, 2025

Via Investor's Business Daily

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zai Lab Limited - ZLAB

September 06, 2025

From Pomerantz LLP

Via GlobeNewswire

Amgen Faces Setback As Final Data Weakens Case For Gastric Cancer Drug ↗

September 04, 2025

Via Benzinga

C3.ai Posts Downbeat Results, Joins GitLab, Salesforce And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

September 04, 2025

Via Benzinga

Zai Lab Announces Approval of TIVDAK® for Patients with Recurrent or Metastatic Cervical Cancer in Hong Kong

September 01, 2025

From Zai Lab Limited

Via Business Wire

Zai Lab Announces Participation in Investor Conferences in September 2025

August 28, 2025

From Zai Lab Limited

Via Business Wire

Zai Lab Announces China National Medical Products Administration Grants Innovative Medical Device Designation for Tumor Treating Fields for Patients with Pancreatic Cancer

August 19, 2025

From Zai Lab Limited

Via Business Wire

Zai Lab Establishes Oncology Scientific Advisory Board

August 13, 2025

From Zai Lab Limited

Via Business Wire

Zai Lab Announces Second Quarter 2025 Financial Results and Recent Corporate Updates

August 07, 2025

From Zai Lab Limited

Via Business Wire

Netflix, BlackSky Technology And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

July 18, 2025

Via Benzinga

Zai Lab to Announce Second Quarter 2025 Financial Results and Recent Corporate Updates on August 7, 2025

July 10, 2025

From Zai Lab Limited

Via Business Wire

Amgen's Gastric Cancer Drug Improves Survival In Phase 3, Notes Ocular Side Effects ↗

June 30, 2025

Via Benzinga

Zai Lab Announces Positive Topline Phase 3 Results for Bemarituzumab in Fibroblast Growth Factor Receptor 2b (FGFR2b) Positive First-Line Gastric Cancer

June 30, 2025

From Zai Lab Limited

Via Business Wire

ZAI LAB LTD-ADR (NASDAQ:ZLAB) – A High-Growth Biotech Stock Meeting Minervini’s Criteria ↗

June 16, 2025

Via Chartmill

Zai Lab Presents New Preclinical Data for ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis, at EAACI Congress 2025

June 13, 2025

From Zai Lab Limited

Via Business Wire

Frequently Asked Questions

Is Zai Lab Limited - American Depositary Shares publicly traded?

Yes, Zai Lab Limited - American Depositary Shares is publicly traded.

What exchange does Zai Lab Limited - American Depositary Shares trade on?

Zai Lab Limited - American Depositary Shares trades on the Nasdaq Stock Market

What is the ticker symbol for Zai Lab Limited - American Depositary Shares?

The ticker symbol for Zai Lab Limited - American Depositary Shares is ZLAB on the Nasdaq Stock Market

What is the current price of Zai Lab Limited - American Depositary Shares?

The current price of Zai Lab Limited - American Depositary Shares is 19.68

When was Zai Lab Limited - American Depositary Shares last traded?

The last trade of Zai Lab Limited - American Depositary Shares was at 12/03/25 11:26 AM ET

What is the market capitalization of Zai Lab Limited - American Depositary Shares?

The market capitalization of Zai Lab Limited - American Depositary Shares is 18.83B

How many shares of Zai Lab Limited - American Depositary Shares are outstanding?

Zai Lab Limited - American Depositary Shares has 19B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.